Image

A Neuro-cognitive and Psychosocial Intervention Module in People With Epilepsy

A Neuro-cognitive and Psychosocial Intervention Module in People With Epilepsy

Recruiting
18-45 years
All
Phase N/A

Powered by AI

Overview

Patients with epilepsy, especially drug-resistant epilepsy, have a lot of cognitive & psycho-social issues. There is little evidence pertaining to the efficacy of the various cognitive-behavioral interventions and cognitive retraining modules used in epilepsy patients in the Indian context. The real value of these interventions needs further consolidation in terms of its assessment and efficacy. The available literature is scanned and having limitations in terms of assessment tool used, sample size, and also lacks a broader spectrum of psychosocial interventions used. In view of the above limitations, we plan to specially develop & test a Neuro-cognitive and psychosocial intervention module, based on the deficits found in these domains that will help DRE patients to improve their quality of life. This module will be covering not only the broader spectrum of assessment tools but also varieties of interventions. This module will help in planning the future needs of epileptic patients in terms of not only medication but also guide us in choosing the kind of interventions to be used with a particular patient or group of patients.

Description

We plan to specially develop & test a Neuro-cognitive and psychosocial intervention module, based on the deficits found in these domains that will help DRE patients to improve their quality of life. This module will be covering not only the broader spectrum of assessment tools but also varieties of interventions.

AIM To develop and test the efficacy of Neuro-cognitive and psychosocial intervention module in drug-resistant epilepsy.

Clinical Sample: The sample will consist of patients with Drug-resistant epilepsy (DRE). Patients with Drug-resistant epilepsy (DRE) will be included per inclusion and exclusion criteria. The subjects will be taken from the patients attending Refractory epilepsy clinic (REC), Department of Neurology, PGIMER, Chandigarh.

Informed written consent will be obtained from all the study participants per the rules and regulations of the Institutional Ethics Committee of PGIMER.

Study design: It will be a pre and post-design. Subjects fulfilling the inclusion and exclusion criteria will be randomly assigned to intervention and control groups-a Hospital-based Randomized Control Trial Study.

Sample Size: n=60 Follow-up Schedule - Both Pre and post-neuropsychological and psychosocial assessments will be done for all patients.

  1. Intervention group - will have an intervention module between pre and post-assessment.
  2. Control group - only follow up between Pre and post-assessment. All the randomized patients will be followed up for outcome assessment at 3 to 6 months of the recruitment (Depending on the module).

Statistical Justification:

  1. Descriptive statistics will be used in terms of frequency, percentages, range, means, and standard deviations.
  2. Group differences between intervention and control groups will be carried out using a t-test.
  3. Correlations will be carried out among all the clinical and neuropsychological variables.
  4. Linear stepwise regression analysis will be carried out for clinical, neuropsychological, and psychosocial variables separately.
  5. Other appropriate statistics would be used as per the requirements of the study.

Eligibility

Inclusion Criteria:

  1. Participants of 18 - 45 years of age.
  2. either gender
  3. Willing to participate and sign the informed consent

Exclusion Criteria:

  1. Patients with other neurological disorders
  2. any other trial at inclusion
  3. should not have any major psychiatric disorder
  4. pregnant and lactating mothers
  5. also, patients who would not be giving informed consent
  6. Patients with intellectual disabilities.

Study details
    Drug Resistant Epilepsy

NCT06537986

Post Graduate Institute of Medical Education and Research, Chandigarh

21 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.